Abstract Details

Title Barriers to Physical Activity among Adults with Idiopathic Parkinson's Disease (PD)

Topic Movement Disorders

Presentation(s) P04 - (-)

Poster/Presentation
Number 151

Objective

Background BACKGROUND: Despite attention given to exercise and health promotion over the last decade, specific studies on exercise preferences and barriers to exercise among persons with PD are scarce and results are conflicting.

Design/Methods DESIGN/METHODS: We administered a validated instrument on physical activity and structured exercise - the Barriers to Physical Exercise in Disability Survey (Rimmer et al., 2002) to a convenience sample of 11 ambulatory patients with PD. Data were analyzed using descriptive statistics.

Results RESULTS: Respondent characteristics: 63% male; 63.0±6.3 years of age; 1.5±1.5 years post-diagnosis; H&Y I and II; PDQ-39 22.0±13.5; MMSE 28.5±1.9; CES-D 9.4±6.3. Top three physical exercise preferences were: yard work (72%), strengthening (63%); and housework (54%). All respondents reported 1 or more barriers to exercise participation. The top five barriers were: lack of motivation (72%) and time (63%), no equipment at home (54%), laziness (50%), lack of energy (40%). Ninety percent wanted to begin an exercise program tailored to their needs but were restricted by the barriers reported. The majority belief was that "exercise will not worsen my condition", but 54% reported "my doctor never told me to do any specific exercise". In 63% of the sample, an exercise program had been developed by the patient or caregiver. Less than 50% had ever been to a physical therapist. 54% believed "an exercise instructor in a fitness center would not know how to set up an exercise program for me".

Conclusions CONCLUSIONS: Adults with PD are interested in becoming more physically active but are limited in doing so because of their inability to overcome several barriers to increased physical activity participation. Barriers due to non-motor features or lack of trained personnel may be modifiable. The study needs to be replicated in a larger sample.

Authors/Disclosures
Danielle Englert, MD PRESENTER	Dr. Englert has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Boston Scientific. Dr. Englert has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Kyowa Kirin. Dr. Englert has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Abbvie. Dr. Englert has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for adamas. Dr. Englert has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for acadia.
	No disclosure on file
Mohammed S. Sanjak, PhD (Carolinas Healthcare System)	No disclosure on file
	No disclosure on file
	No disclosure on file
Gary R. Cutter, PhD (University of Alabama At Birmingham)	Dr. Cutter has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for onsulting or Advisory Boards: Alexion, Antisense Therapeutics/Percheron, Avotres, Biogen, Clene Nanomedicine, Clinical Trial Solutions LLC, Endra Life Sciences, Cognito Therapeutics, Genzyme, Genentech, Immunic, Klein-Buendel Incorporated, Kyverna Therapeutics, Inc. , Linical, Merck/Serono, Noema, Neurogenesis, Perception Neurosciences, Protalix Biotherapeutics, Regeneron, Revelstone Consulting, Roche, SAB Biotherapeutics, Sapience Therapeutics, Scott&Scott LLP, Tenmile.. Dr. Cutter has received personal compensation in the range of $50,000-$99,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Data and Safety Monitoring Boards: Applied Therapeutics, AI therapeutics, AMO Pharma, Argenx, Astra-Zeneca, Avexis Pharmaceuticals, Bristol Meyers Squibb, CSL Behring, Cynata Therapeutics, DiamedicaTherapeutics, Horizon Pharmaceuticals, Immunic, Inhibrix, Karuna Therapeutics, Kezar Life Sciences, Medtronic, Merck, Meiji Seika Pharma, Mitsubishi Tanabe Pharma Holdings, Prothena Biosciences, Novartis, Pipeline Therapeutics (Contineum), Regeneron, Sanofi-Aventis, Teva Pharmaceuticals, United BioSource LLC, University of Texas Southwestern.. Dr. Cutter has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for JASN.
	No disclosure on file
Sanjay S. Iyer, MD (Memory and Movement Charlotte)	Dr. Iyer has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for TEVA. Dr. Iyer has received personal compensation in the range of $50,000-$99,999 for serving on a Speakers Bureau for Neurocrine. Dr. Iyer has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Adamas. Dr. Iyer has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for USWM.

��ɫ��

��ɫ��